Syndax Pharmaceuticals (SNDX) Preferred Stock Liabilities (2015)

Syndax Pharmaceuticals (SNDX) recorded quarterly Preferred Stock Liabilities of $319.1 million in Q4 2015.

Syndax Pharmaceuticals (SNDX) Preferred Stock Liabilities (2015) Analysis & Trends

Syndax Pharmaceuticals' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $319.1 million for Q4 2015.

In Q4 2015, Preferred Stock Liabilities changed N/A year-over-year to $319.1 million; the TTM figure through Dec 2015 stood at $319.1 million (changed N/A YoY), while the FY2015 annual figure was $319.1 million, up 117.3% from the prior year.
Preferred Stock Liabilities was $319.1 million for Q4 2015 at Syndax Pharmaceuticals.
In the past five years, Preferred Stock Liabilities ranged from a high of $319.1 million in Q4 2015 to a low of $319.1 million in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Syndax Pharmaceuticals	1.69 Bn	1.34 Bn	53.02 Mn	-

Download Data

Date	Value
Dec 31, 2015	319.11 Mn